Two sets of myeloma real-world and clinical observations sharpen how earlier and extended use of cell and T-cell engagers may be managed. A real-world study reports that ciltacabtagene autoleucel (cilta-cel) achieved a 98.0% overall response rate in relapsed or refractory multiple myeloma treated after one to three prior therapies, alongside deep minimal residual disease clearance. Separately, an observational correspondence in *Experimental Hematology and Oncology* describes six patients who remained on extended-interval teclistamab and talquetamab without repeating step-up dosing across 8 to 12 week gaps. The authors report no acute inflammatory toxicities during those extended dosing windows, despite high rates of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome during initial step-up periods. Together, the reports point toward more aggressive treatment sequencing and potentially simplified scheduling—provided patients have already achieved deep response and are monitored for late toxicities including infection risk and cytopenias.